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Sm_ry The proliferating cell nuclear antigen (PCNA) is required for DNA replication and DNA
nucleotide excision repair. Considerable evidence points to PCNA expression being a marker of proliferation
in many situations. However, while levels of PCNA are normally very low in non-cycling tissues, high levels of
the protein have been observed in the normal tissues surrounding human breast and pancreatic tumours.
Using two model systems we have shown that PCNA is induced in non-cycling cells by adjacent transplanted
tumour cells and that this phenomenon may be mimicked by the in vivo administration of growth factors
(transforming growth factor a and epidermal growth factor). These data suggest that tumours may elaborate
factors that induce PCNA expression in nearby normal cells. PCNA induction in the normal cells surrounding
tumours is a direct example of the effect of tumour cells on normal surrounding tissues. This effect may prove
to be a useful parameter in the analysis of tumour-host interactions.
Proliferating cell nuclear antigen (PCNA) is an evolutionarily
conserved 36 kDa nuclear protein that by functioning as a
co-factor for DNA polymerase 6 is an absolute requirement
for semiconservative DNA synthesis (Bravo & MacDonald-
Bravo, 1987; Suzuka et al., 1989; Baserga, 1991). Levels of
PCNA are almost negligible in long-term quiescent cells and
increase dramatically during the cell cycle. Recently there has
been considerable interest in the application of antibodies to
PCNA as operational markers of proliferation in histological
material (Hall & Levison, 1990; McCormick & Hall, 1992).
The rationale for this approach is the ability of several
anti-PCNA antibodies to recognise fixation- and processing-
resistant epitopes (Hall et al., 1990; McCormick & Hall,
1992), thus allowing the possibility of objectively quantifying
the number of cycling cells in tissue sections. One particular
commercially available antibody, clone PCIO (Waseem &
Lane, 1990), has been widely employed in pathology in this
context.
In the original description of the application of this rea-
gent to pathological material, Hall et al. (1990) reported that,
in addition to important technical caveats on its use, the
number of PCIO-immunoreactive cells appeared to exceed
that expected in certain situations, most notably in neoplasia.
Part of the explanation for the expression of PCNA in
non-cycling cells lies in the long half-life of the PCNA pro-
tein (Bravo et al., 1987). Support for this interpretation was
provided by detailed kinetic studies of tumour xenografts
(Scott et al., 1991). It has also been shown that PCNA
participates in DNA repair processes. Tightly bound PCNA
can be found associated with chromatin at all phases of the
cell cycle after UV irradiation in vitro (Celis & Madsen, 1986;
Toschi & Bravo, 1988), and PCNA has been shown to an
obligate requirement for DNA nucleotide excision repair
(Shivji et al., 1992). PCNA may be expressed by non-cycling
cells in vivo which are undergoing DNA repair (Hall et al.,
1993). However, this cannot explain all the situations in
which 'aberrant' PCNA expression has been observed.
In several organs, notably breast, liver and pancreas, nor-
mal tissues adjacent to tumours show high levels of PCNA
expression that appears not to be associated with prolifera-
tion (Hall et al., 1990; Pelosi et al., 1992; Harrison et al.,
1993). Based upon the observations of Baserga and co-
workers (Chang et al., 1990; Ottavio et al., 1990; Baserga,
1991), Hall et al. (1990) proposed that this may reflect
changes in PCNA regulation in association with neoplasia
and possibly the effect of growth factors on transcriptional
and post-transcriptional processes. In the experiments de-
scribed here we have confirmed, in rodent models, that
tumours can induce PCNA expression (as assessed by PCIO
immunoreactivity) in adjacent normal tissues without there
being concomitant proliferation. We also show that this
effect can be mediated by growth factors in vivo.
MateeaLs and method
In the first set of experiments, human carcinoma cell lines
(LoVo and HT29) were introduced by direct inoculation [106
cells in 0.05 ml of phosphate-buffered saline (PBS)] into the
liver of nude mice. After 21 days the inoculated mice received
a single i.p. injection oftritiated thymidine (1 glCi in 0.1 ml of
PBS; [methyl-3Hlthymidine, 25 Ci mmol ', Amersham Inter-
national, Amersham, UK). One hour later the animals
(n = 6) were killed and xenografts growing in the liver were
removed, fixed in formalin and processed to paraffin for both
immunostaining and autoradiography.
It is known from previous studies that LoVo and HT-29
express growth factors similar to transforming growth factor
(TGF-x) and epidermal growth factor (EGF) (Anano et al.,
1989; Imanishi et al., 1989). Therefore, in a second set of
experiments, rats were given total parenteral nutrition (TPN)
with or without supplements of TGF-x or EGF for 3 days,
as described previously (Goodlad et al., 1987, 1992). In brief,
male Wistar rats (approximately 200 g) were anaesthetised
with 0.7 ml of Hypnorm and 0.07 ml of diazepam (intraperi-
toneal route), and a silastic cannula was tied into the right
external jugular vein. The cannula was connected through a
stainless-steel skin button and tethered to a fluid swivel joint
(SMA, Barnet, UK). The rats were housed individually in
wire-bottomed cages. The TPN diet was pumped into the
rats, from a refrigerator, by a multichannel peristaltic pump,
at a rate of 60 ml per rat per day, giving 1.8 g of nitrogen,
6.0 g of lipid, 8.5 g of glucose and 1,047 kJ kg-' day-'
(Goodlad et al., 1987). There were three groups of 11 rats in
the second study, the first being the (TPN alone) controls;
the second were given 275 jg kg-' TGF-a (J. Fritton, ICI
Macclesfield, Cheshire, UK) and the third were given
300ILg kg-' EGF (M. Edwards, British Biotechnology,
Cowley, Oxford, UK). One hour prior to sacrifice animals
were given tritiated thymidine (1.0 iCi kg-') by i.p. injection.
At the end of the experiments, animals were killed and
tissues (liver and pancreas) were fixed in formalin and pro-
Correspondence: P.A. Hall, Department of Pathology, Ninewells
Hospital and Medicl School, Umversty ofDundee, Dundee DDI 9SY,
UK
Received 14 April 1993; and in revised form 30 March 1994.
Br. J. Cancer (1994), 70, 244-247 C) Macmillan Press Ltd., 1994PCNA EXPRESSION IN NON-CYCLING CELLS 245
cessed to paraffin for both immunostaining and autoradio-
graphy.
PCNA immunoreactivity was identified in both sets of
experiments in the same way using the monoclonal antibody
PC1O by immunohistochemistry as described previously (Hall
et al., 1990), except that the indirect method was employed
(rather than ABC) because of the presence of high levels of
biotin in the liver. The PC1O antibody recognises a highly
conserved epitope on both human and rodent PCNA. Auto-
radiography was performed using standard methods (Good-
lad et al., 1987, 1992). In brief, sections were dehydrated in
alcohols containing 300 mM ammonium acetate, dried,
dipped in Ilford K5 emulsion and exposed for 6-10 days at
4C before development in Kodak D19. Sections were then
counterstained lightly with haemotoxylin.
Quantitation of PCNA expression was performed on an
Olympus BH2 microscope by counting positive cells (nuclear
labelling) per 1,000 hepatocytes or pancreatic epithelial cells.
In the pancreas the three morphologically distinct compart-
ments, ducts, acini and islets, were enumerated separately. In
the livers of animals with hepatic xenografts the labelling of
hepatocytes was assessed semiquantitatively with respect to
distance to xenograft in that section. Using a 20 x objective
the proportion of labelled cells within two fields' distance,
between three and four fields' distance and more than four
fields' distance was estimated in order to give some indication
of the gradient of any effect due to the xenograft.
Results
Injection of LoVo or HT29 cells into the liver gave rise to
progressively growing tumour xenografts within the hepatic
parenchyma. The adjacent liver cells appeared morpho-
logically unremarkable, but many showed nuclear PCNA
immunoreactivity (Figure la), although there was little
evidence of thymidine incorporation as an independent assay
of cell proliferation (Figure lb). Quantitation of PCNA
immunoreactive hepatocytes and cells showing thymidine in-
corporation confirmed this qualitative assessment (see Table
I). Specifically, neither HT29 nor LoVo xenografts induced
any cell proliferation compared with that observed in control
Table I Expression of PCNA and thymidine labelling in normal
liver adjaent to xenografts (labelled cells per 1,000 bepatocytes plus
or minus standard deviation)
LoVo HT-29 Control
Thymidine-labelled cells 0.11 0.08 0.10±0.07 0.11±0.04
PCNA expression
Fields 1+ 2 5.21 ±0.45* 5.00 0.34* 1.0± 0.06
Fields 3 + 4 2.21 ± 0.89** 1.91 ± 0.76** 0.98 ± 0.65
Fields 5 and above 1.3 0.56 1.2 0.34 0.87 0.47
Student's t-test LoVo or HT-29 vs control: *P <0.001,
**P <0.01, other comparisons not significant.
Table H PCNA and thymidine incorporation in rats parenterally
fed with or without growth factors (per 1,000 cells plus or minus
standard deviation)
Control TGF-a EGF
Acini
[3H]thymidine 0.09 0.02 0.12 ± 0.03 0.10 ± 0.02
PCNA 0.12±0.04 0.15±0.08 0.16±0.06
Ducts
[3HJthymidine 0.08 ± 0.02 0.09 ± 0.02 0.08 ± 0.03
PCNA 0.12 ±0.04 7.65± 4.22* 5.34± 2.03*
Islets
[3H]thymidine 0.08 ± 0.18 0.08 ± 0.02 0.06 ± 0.03
PCNA 0.11 ± 0.05 0.38 ± 0.07* 0.34 ± 0.04*
Student's t-test vs control: *P <0.001, all other comparisons not
significant.
livers, though there was a significant induction of PCNA
immunoreactivity (P<0.001). The effect of the xenografts
showed a clear gradient as PCNA expression close to the
xenograft was higher than that at a distance (see Table I).
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Figwe I Expression of PCNA in normal bepatocytes adjacent
to a xenograft (a) as compared with the lack of thymidine
incorporation (b).246 P.A. HALL et al.
Isomolar concentrations of TGF-x or EGF induced up- no alteration in thymidine labelling in the TGF-(x- or EGF-
regulation of PCNA expression in the pancreas (Figure 2a treated animals as compared with controls. In addition, there
and b) as compared with control in the ductal and islet was an increase in hepatic PCNA expression compared with
epithelium, but not in the acinar cells (P<O.001). There was control, although no detectable increase in thymidine incor-
poration (Table II).
D ioa
It has been reported previously that, although under many
circumstances PCNA expression correlates well with cell pro-
liferation, apparent deregulation is sometimes observed, such
deregulation occurring particularly in neoplasia (Hall et al.,
1990; Yu et al., 1991; Gillett et al., 1992). Expression of
-_ * ., PCNA immunoreactivity in normal cells adjacent to tumours
when seen may be due to a number of possible mechanisms
# -A (McCormick & Hall, 1992). For example, the long biological
4 EtE f Xk half-life of the PCNA protein allows cells that have recently
left the cell cycle to continue to exhibit PCNA staining (Scott
QW6e i- i- et al., 1991). The involvement of PCNA in DNA nucleotide
excision repair (Shivji et at., 1992) also provides a plausible ffi Kf- r { f ¢ _ ~~~~~~mechanism for expression In neoplastic cells. Excpression of
PCNA in morphologically normal cells adj'acent to tumours
_A e > i_is more difficult to explain. A particular problem has been
the lack of corroborative evidence that the cells expressing
PCNA are indeed not cycling. It has been proposed that this
may reflect the complex regulation of PCNA gene expression
gg - ¢* and the possible role of growth factors in the stabilisation
.02 ,_ +^ and enhanced translation of PCNA mRNA (Chang et al.,
1990; Hall et al., 1990; Ottavio et al., 1990; Shipman-
Appasamy et al., 1990; Baserga, 1991). In order to test this
hypothesis we have performed two sets ofexperiments. In the
*--^ _ _ 6 > - first set we induced small tumour xenografts in the liver, a
conditional renewal tissue composed of non-cycling cells
which are capable of entering the cell cycle after a suitable -_IIIE hIII stimulus. In the second set of studies we employed an intra-
venous delivery system to infuse a controlled dose of either
EGF or TGF-a. We chose to examine the effects on the
pancreas since we have previously reported the spatial distri-
_ _V, > 3;.>Z bution of the cognate receptor for these growth factors (Bar-
_0 * <ton et al., 1991; Lemoine et al., 1992). In both sets of
experiments we employed thymidine labelling as a well-
established external marker of cell proliferation.
The first set of experiments provides direct evidence that
Nk:, the observations made on clinical material are real, i.e. that
in association with neoplasia normal tissues can be induced
to express PCNA immunoreactivity as detected by PC1O
(Figure 1) without there being any evidence that the cells are
entering the cell cycle (Figure I and Table I). These
experiments do not, however, give any insight into the
mechanisms underpinning this phenomenon. While the possi-
.0<v - bility of mechanical effects cannot at present be excluded, it
may also be that the expression of growth factors by the 4 , _ , ^+ t :X£ tumour cells (or adjacent cells) could induce PCNA expres-
sion. The second set of experiments provide evidence for a
mechanism involving growth factors. The identification of
PCNA immunoreactivity greatly in excess (P<0.001) of that
seen in controls in those animals given TGF-a or EGF
parenterally over prolonged periods indicates that growth
factors can induce PCNA expression without entry into the
cell cycle. Furthermore, the observation that the spatial dist-
*¶ 8 nribution of abnormal PCNA expression (Figure 2) is
primarily seen in ducts (and to a much lesser extent in islets)
with no expression in acinar cells is consistent with the
distribution of EGF receptor expression as demonstrated
inimunohistologically (Lemoine et al., 1992).
Recently Harrison et al. (1993) have shown a clear up-
regulation of PCNA in normal hepatocytes adjacent to a
range of pathological lesions. Furthermore, they demon-
strated that there is a discordance between PCNA and pro-
liferation as judged by expression of the Ki67 antigen. Our
Fiwe 2 Expression of PCNA in the pancreatic duct cells from data indicate that this and other observations made in
an animal given TPN and TGF-x (a). In the pancreas from clinical material [abnormal expression of PCNA in associa-
control animals given TPN alone there is very little thymidine tion with tumours (Hall et al., 1990; Pelosi et al., 1992)]is a
incorporation (b). real phenomenon, and we provide evidence that growth fac-PCNA EXPRESSION IN NON-CYCLING CELLS 247
tors can mediate expression of PCNA without the need for
cells to enter the cell cycle. This should lead to considerable
caution in using antibodies to PCNA as immunohistological
determinants of cell proliferation without careful validation.
In addition to being relevant to the use of antibodies to
PCNA in pathology (McCormick et al., 1992), these observa-
tions are of broader biological interest. They suggest that
cells surrounding many human tumours are placed in a
different environment to the normal cells of that tissue. Our
previous observations (Hall et al., 1990) on the expression of
PCNA suggest that the extent of this effect is variable
between different cases and it may thus provide an additional
parameter of tumour behaviour. In particular, it will be of
interest to determine whether the induction of PCNA
immunoreactivity in normal tissues adjacent to a neoplasm
provides an index of the behaviour of that tumour.
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